Non Alcoholic Steatohepatitis Biomarkers Market Share [2031]
Non Alcoholic Steatohepatitis Biomarkers Market Share [2031]
Segments - Non-alcoholic Steatohepatitis Biomarkers Market by Types (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, and Others), End-users (Pharma & CRO Industry, Hospitals, Diagnostic Labs, and Academic Research Institutes), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031.
Upcoming
| Report ID :HC-960
| 4.6 Rating
| 80 Reviews
| 187 Pages
| Format :
Report Description
Non-alcoholic Steatohepatitis Biomarkers Market Outlook 2031
The global non-alcoholic steatohepatitis biomarkers market size was USD 982.15 Million in 2022 and is projected to reach USD 6.61 Billion by 2031 expand at a substantial CAGR 23.6% during the forecast period, 2023–2031. The growth of the market is attributed to the increasing incidence of chronic liver conditions, which has resulted to increase demand for non-invasive diagnostic tools.
The prevalence of non-alcoholic steatohepatitis (NASH) has increased over the recent years and the adoption of NASH biomarkers since it leads to liver failure as a consequence. According to a health report, around 20% patients in the US are suffering from NASH disease and are susceptible to cirrhosis-a condition in which scar tissues replaces healthy tissues and around 10% becomes the victims of the disease.
As per a study in 2009 by the United States Census Bureau, around 13% of total US population were represented by people attaining the age of 65 and above older people and the trend is projected to rise up to 20% by 2030.
Nonalcoholic fatty liver disease (NAFLD) is accurately diagnosed by the use of several devices such as magnetic resonance imaging, ultrasound scanning, and computed tomography, which are imaging techniques. However, the adoption of these imaging techniques are not sufficient for NASH detection or liver fibrosis detection. Due to this, it is expected that these factors are responsible for increasing in demand of noninvasive diagnostic tools in the coming years.
Growing initiatives for the development of NASH drugs is one of the factor responsible for NASH biomarkers market growth. In 2016, GENFIT, one of the biopharmaceutical company has launched the NASH Education Program. This program was aimed for generating awareness about NASH among patients. Moreover, the company introduced pediatric NAFLD/NASH Program in Europe by taking approval by elafibranor’s pediatric investigation plan by the European Medicine Agency, which is expected to aid drug development program in the coming years.
Non-alcoholic Steatohepatitis Biomarkers Market Trends, Drivers, Restraints, and Opportunities
- Increasing cases of liver diseases and failures due to NASH conditions are key factors driving the market expansion during the forecast period.
- Growing demand of noninvasive diagnostic tools and increasing awareness of advanced NASH biomarkers are expected to boost the market.
- Lower implementation of invasive techniques due to lower acceptance by patients, expensive liver biopsy, and invasiveness for disease diagnosis are key challenges that can impede the market expansion.
- The COVID-19 pandemic has affected the non-alcoholic steatohepatitis biomarkers market due to emergency lockdowns forcing to shut the manufacturing, production chain, and other required operations.
- Technological advancement and ongoing R&D activities to improve the biomarkers and diagnostic devices are projected to offer significant opportunities for the market players.
Scope of The Non-alcoholic Steatohepatitis Biomarkers Market Report
The report on the global non-alcoholic steatohepatitis biomarkers market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Non-alcoholic Steatohepatitis Biomarkers Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Types (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, and Others) and End-Users (Pharma & CRO Industry, Hospitals, Diagnostic Labs, and Academic Research Institutes) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
GENFIT Gilead, AstraZeneca, Novartis AG, Bristol-Myers Squibb, Allergan Novo Nordisk A/S, Boehringer Ingelheim GmbH, and Pfizer, Inc. |
Non-alcoholic Steatohepatitis Biomarkers Market Segment Insights
Serum biomarkers segment is projected to hold a large market share
Based on types, the non-alcoholic steatohepatitis biomarkers market is divided into serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others. The serum biomarkers segment accounted for a large market share in 2020 and is anticipated to expand at a rapid pace during the forecast period due to its benefits such as efficient outcome and capability to differentiate simple steatosis from NASH.
The serum biomarkers are widely used for detecting NASH and the production of new technology to diagnose the level of free fatty acids, apolipoprotein A1, leptin, ghrelin & tumor necrosis factor-alpha, adiponectin and apolipoprotein B are boosting the segment growth. The serum biomarkers are also found in various applications such as diagnosis of ovarian, colorectal, prostate, and lung and breast-related disorders.
However, the hepatic fibrosis biomarkers segment is projected to exhibit a rapid growth rate during the forecast period due to efficiency and high accuracy. The hepatic fibrosis biomarkers are considered to be attractive and affordable alternative for physicians and patients for the diagnosis of diseases.
Pharma & CRO industry segment is expected to grow at a rapid pace
On the basis of end-users, the market is segmented into pharma & CRO industry, hospitals, diagnostic labs, and academic research institutes. The pharma and CROs industry accounted for a major market share in 2019 and is projected to expand at a significant growth rate over the forecast period. Growing demand for noninvasive NASH diagnostic and monitoring tools for clinical trials are responsible for the segment growth.
Many companies are doing research on NASH therapeutics. Some factors such as high cost of treatment, complex pathophysiology, and unknown etiology are projected to restrain the revenue growth of this segment.
A noninvasive technique is preferred during clinical trials for routine monitoring of drug therapy, which is anticipated to fuel the growth of hospitals and diagnostics segment. After the drug launch in hospitals and diagnostic laboratories, the use of biomarkers are widely practices, which is projected to grow the segment growth. Hence, the hospitals and diagnostic laboratories segment is projected to show rapid growth over the forecast period.
North America is expected to dominate the market
In terms of regions, the non-alcoholic steatohepatitis biomarkers market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to expand at an impressive CAGR during the forecast period. In North America, these factors such as wide prevalence of cardiovascular diseases, favorable government initiatives, cancer and increasing occurrence of infectious diseases are responsible for the regional market growth.
The drug development activities are supported by key players with allocating a large funding for research and development for the production of innovative biomarkers, which are expected to propel the regional market growth.
The market in Asia Pacific is anticipated to constitute a large market share in the coming years owing to the rising expansion of several diagnostics centers and clinical labs due to rising spending on research and development. The players based in countries such as China and Japan are increasing their spending on R&D, which leads to market growth. The US and European companies are willing to invest in Asia Pacific because of factors such as cheaper clinical trials and immense target population. This is projected to propel the regional market growth.
Segments
The global non-alcoholic steatohepatitis biomarkers market has been segmented on the basis of
Types
- Serum Biomarkers
- Hepatic Fibrosis Biomarkers
- Apoptosis Biomarkers
- Oxidative Stress Biomarkers
- Others
End-Users
- Pharma & CRO Industry
- Hospitals
- Diagnostic Labs
- Academic Research Institutes
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- GENFIT
- Gilead
- AstraZeneca
- Novartis AG
- Bristol-Myers Squibb
- Allergan Novo Nordisk A/S
- Boehringer Ingelheim GmbH
- Pfizer, Inc.
Competitive Landscape
Key players competing in the non-alcoholic steatohepatitis biomarkers market include GENFIT Gilead, AstraZeneca, Novartis AG, Bristol-Myers Squibb, Allergan Novo Nordisk A/S, Boehringer Ingelheim GmbH, and Pfizer, Inc.
Some of these players are implementing several business strategies including mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. Existing market players, having less diversified product portfolio, are competing with new players to enter with their diversified and innovative product portfolios. Moreover, new players enter in the market due to growing demand of accurate and efficient diagnostics.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Non-alcoholic Steatohepatitis Biomarkers Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Non-alcoholic Steatohepatitis Biomarkers Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Non-alcoholic Steatohepatitis Biomarkers Market - Supply Chain
4.5. Global Non-alcoholic Steatohepatitis Biomarkers Market Forecast
4.5.1. Non-alcoholic Steatohepatitis Biomarkers Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Non-alcoholic Steatohepatitis Biomarkers Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Non-alcoholic Steatohepatitis Biomarkers Market Absolute $ Opportunity
5. Global Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Non-alcoholic Steatohepatitis Biomarkers Market Size and Volume Forecast by Types
5.3.1. Serum Biomarkers
5.3.2. Hepatic Fibrosis Biomarkers
5.3.3. Apoptosis Biomarkers
5.3.4. Oxidative Stress Biomarkers
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast by End Users
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by End Users
6.2.2. Y-o-Y Growth Projections by End Users
6.3. Non-alcoholic Steatohepatitis Biomarkers Market Size and Volume Forecast by End Users
6.3.1. Pharma & CRO Industry
6.3.2. Hospitals
6.3.3. Diagnostic Labs
6.3.4. Academic Research Institutes
6.4. Absolute $ Opportunity Assessment by End Users
6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Non-alcoholic Steatohepatitis Biomarkers Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Non-alcoholic Steatohepatitis Biomarkers Demand Share Forecast, 2019-2026
8. North America Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Non-alcoholic Steatohepatitis Biomarkers Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Non-alcoholic Steatohepatitis Biomarkers Market Size and Volume Forecast by Types
8.4.1. Serum Biomarkers
8.4.2. Hepatic Fibrosis Biomarkers
8.4.3. Apoptosis Biomarkers
8.4.4. Oxidative Stress Biomarkers
8.4.5. Others
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. North America Non-alcoholic Steatohepatitis Biomarkers Market Size and Volume Forecast by End Users
8.7.1. Pharma & CRO Industry
8.7.2. Hospitals
8.7.3. Diagnostic Labs
8.7.4. Academic Research Institutes
8.8. Basis Point Share (BPS) Analysis by End Users
8.9. Y-o-Y Growth Projections by End Users
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Non-alcoholic Steatohepatitis Biomarkers Demand Share Forecast, 2019-2026
9. Latin America Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Non-alcoholic Steatohepatitis Biomarkers Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Non-alcoholic Steatohepatitis Biomarkers Market Size and Volume Forecast by Types
9.4.1. Serum Biomarkers
9.4.2. Hepatic Fibrosis Biomarkers
9.4.3. Apoptosis Biomarkers
9.4.4. Oxidative Stress Biomarkers
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Latin America Non-alcoholic Steatohepatitis Biomarkers Market Size and Volume Forecast by End Users
9.7.1. Pharma & CRO Industry
9.7.2. Hospitals
9.7.3. Diagnostic Labs
9.7.4. Academic Research Institutes
9.8. Basis Point Share (BPS) Analysis by End Users
9.9. Y-o-Y Growth Projections by End Users
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Non-alcoholic Steatohepatitis Biomarkers Demand Share Forecast, 2019-2026
10. Europe Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Non-alcoholic Steatohepatitis Biomarkers Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Non-alcoholic Steatohepatitis Biomarkers Market Size and Volume Forecast by Types
10.4.1. Serum Biomarkers
10.4.2. Hepatic Fibrosis Biomarkers
10.4.3. Apoptosis Biomarkers
10.4.4. Oxidative Stress Biomarkers
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Europe Non-alcoholic Steatohepatitis Biomarkers Market Size and Volume Forecast by End Users
10.7.1. Pharma & CRO Industry
10.7.2. Hospitals
10.7.3. Diagnostic Labs
10.7.4. Academic Research Institutes
10.8. Basis Point Share (BPS) Analysis by End Users
10.9. Y-o-Y Growth Projections by End Users
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Non-alcoholic Steatohepatitis Biomarkers Demand Share Forecast, 2019-2026
11. Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Size and Volume Forecast by Types
11.4.1. Serum Biomarkers
11.4.2. Hepatic Fibrosis Biomarkers
11.4.3. Apoptosis Biomarkers
11.4.4. Oxidative Stress Biomarkers
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Size and Volume Forecast by End Users
11.7.1. Pharma & CRO Industry
11.7.2. Hospitals
11.7.3. Diagnostic Labs
11.7.4. Academic Research Institutes
11.8. Basis Point Share (BPS) Analysis by End Users
11.9. Y-o-Y Growth Projections by End Users
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Demand Share Forecast, 2019-2026
12. Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market Size and Volume Forecast by Types
12.4.1. Serum Biomarkers
12.4.2. Hepatic Fibrosis Biomarkers
12.4.3. Apoptosis Biomarkers
12.4.4. Oxidative Stress Biomarkers
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market Size and Volume Forecast by End Users
12.7.1. Pharma & CRO Industry
12.7.2. Hospitals
12.7.3. Diagnostic Labs
12.7.4. Academic Research Institutes
12.8. Basis Point Share (BPS) Analysis by End Users
12.9. Y-o-Y Growth Projections by End Users
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Non-alcoholic Steatohepatitis Biomarkers Market: Market Share Analysis
13.2. Non-alcoholic Steatohepatitis Biomarkers Distributors and Customers
13.3. Non-alcoholic Steatohepatitis Biomarkers Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. GENFIT
13.4.2. Gilead
13.4.3. AstraZeneca
13.4.4. Novartis AG
13.4.5. Bristol-Myers Squibb
13.4.6. Allergan Novo Nordisk A/S
13.4.7. Boehringer Ingelheim GmbH
13.4.8. Pfizer, Inc.
Methodology
Related Reports
Some other reports from this category!
Our Clients
